ENTRY       D00896                      Drug
NAME        Efavirenz (JAN/USP/INN);
            Sustiva (TN)
  ABBR      EFV
PRODUCT     SUSTIVA (Bristol-Myers Squibb Pharma Company)
  GENERIC   EFAVIRENZ (Aurobindo Pharma Limited)
            EFAVIRENZ (Aurobindo Pharma Limited)
            EFAVIRENZ (Camber Pharmaceuticals)
            EFAVIRENZ (Cipla USA)
            EFAVIRENZ (Golden State Medical Supply)
            EFAVIRENZ (REMEDYREPACK)
            EFAVIRENZ (Rising Pharmaceuticals)
            EFAVIRENZ (Strides Pharma Science Limited)
            EFAVIRENZ (Strides Pharma)
            EFAVIRENZ (XLCare Pharmaceuticals)
FORMULA     C14H9ClF3NO2
EXACT_MASS  315.0274
MOL_WEIGHT  315.675
CLASS       Antiviral
             DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
             DG03107  Anti-HIV agent
              DG01656  HIV reverse transcriptase inhibitor
            Metabolizing enzyme substrate
             DG02919  CYP2B6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inducer
             DG02891  CYP2B6 inducer
             DG02853  CYP3A/CYP3A4 inducer
              DG01635  CYP3A4 inducer
REMARK      Same as: C08088
            Therapeutic category: 6250
            ATC code: J05AG03
            Product: D00896<JP/US>
            Product (mixture): D10851<US> D11392<US>
EFFICACY    Antiviral, Reverse transcriptase inhibitor
  DISEASE   HIV-1 infection [DS:H01563]
TARGET      HIV-1 reverse transcriptase [KO:K24802]
  PATHWAY   ko03230(K24802)  Viral genome structure
            ko03240(K24802)  Viral replication
            ko03250(K24802)  Viral life cycle - HIV-1
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP2B6 [HSA:1555]
INTERACTION CYP induction: CYP2B6 [HSA:1555], CYP3A4 [HSA:1576]
STR_MAP     map07053  Anti-HIV agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AG Non-nucleoside reverse transcriptase inhibitors
                 J05AG03 Efavirenz
                  D00896  Efavirenz (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)
               Efavirenz
                D00896  Efavirenz (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D00896  Efavirenz (JAN/USP/INN)
            Drug groups [BR:br08330]
             Antiviral
              DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
               D00896  Efavirenz
              DG03107  Anti-HIV agent
               DG01656  HIV reverse transcriptase inhibitor
                D00896  Efavirenz
             Metabolizing enzyme substrate
              DG02919  CYP2B6 substrate
               D00896  Efavirenz
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D00896  Efavirenz
             Metabolizing enzyme inducer
              DG02891  CYP2B6 inducer
               D00896  Efavirenz
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                D00896  Efavirenz
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D00896  Efavirenz
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV reverse transcriptase inhibitor
                D00896  Efavirenz (JAN/USP/INN) &lt;JP/US&gt;
            Antimicrobials abbreviations [BR:br08327]
             Antivirals
              Genome replication inhibitor
               HIV reverse transcriptase inhibitor
                D00896  Efavirenz (JAN/USP/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00896
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00896
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D00896
DBLINKS     CAS: 154598-52-4
            PubChem: 7847960
            ChEBI: 119486
            PDB-CCD: EFZ
            LigandBox: D00896
            NIKKAJI: J727.577C
ATOM        21
            1   C1z C    22.0907  -17.8033
            2   C8y C    20.8724  -18.4968
            3   C3b C    23.0815  -16.8124
            4   O7x O    23.3087  -18.5085
            5   C1d C    20.8724  -17.1096
            6   C8y C    20.8724  -19.8957
            7   C8x C    19.6776  -17.7974
            8   C3b C    24.0607  -15.8216
            9   C7x C    23.2970  -19.9074
            10  X   F    19.4676  -17.1039
            11  X   F    20.4935  -15.7516
            12  X   F    21.8457  -16.1130
            13  N1x N    22.0790  -20.6069
            14  C8x C    19.6776  -20.6009
            15  C8y C    18.4534  -18.4968
            16  C1y C    25.0457  -14.8248
            17  O6a O    24.5036  -20.6126
            18  C8x C    18.4534  -19.8957
            19  X   Cl   17.2352  -17.7974
            20  C1x C    26.3922  -14.4634
            21  C1x C    25.3954  -13.4783
BOND        23
            1     1   2 1
            2     1   3 1 #Down
            3     1   4 1
            4     1   5 1 #Up
            5     2   6 2
            6     2   7 1
            7     3   8 3
            8     4   9 1
            9     5  10 1
            10    5  11 1
            11    5  12 1
            12    6  13 1
            13    6  14 1
            14    7  15 2
            15    8  16 1
            16    9  17 2
            17   14  18 2
            18   15  19 1
            19   16  20 1
            20   16  21 1
            21    9  13 1
            22   15  18 1
            23   20  21 1
///
